Clinical TrialID 1600
Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain
NCT01929044
Intestinal Diseases
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 1600
- Evidence Id
- 1600
- Core Evidence Id
- 1600
- Source Clinical Trial Id
- 1574
- Herb2 Clinical Trial Id
- HBCT001574
- Nct Id
- NCT01929044
- Title
- Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain
- Status
- Completed
- Phase
- Phase 3
- Study Result
- Yes
- Study Condition
- Intestinal Diseases
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
- Intervention
- DRUG: 654-II (anisodamine)|DRUG: Buscopan® (hyoscine butylbromide)
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 299
- Outcome Measure
- PID From Pre-dose Baseline at 20 Minutes After First Injection., Pain intensity difference (PID) from pre-dose baseline at 20 minutes after first injection. It was assessed using an 11-point numerical rating scale (NRS) ranging from 0 = 'no pain' to 10 = 'worst pain possible'., Baseline and 20 minutes after the first injection
- Sponsor Collaborator
- Boehringer Ingelheim
- Funded By
- INDUSTRY
- Location
- 202.848.86016 Boehringer Ingelheim Investigational Site, Baotou, China|202.848.86008 Boehringer Ingelheim Investigational Site, Beijing, China|202.848.86009 Boehringer Ingelheim Investigational Site, Beijing, China|202.848.86010 Boehringer Ingelheim Investigational Site, Beijing, China|202.848.86013 Boehringer Ingelheim Investigational Site, Beijing, China|202.848.86012 Boehringer Ingelheim Investigational Site, Changchun, China|202.848.86020 Boehringer Ingelheim Investigational Site, Changsha, China|202.848.86018 Boehringer Ingelheim Investigational Site, Chenzhou, China|202.848.86007 Boehringer Ingelheim Investigational Site, Chongqing, China|202.848.86021 Boehringer Ingelheim Investigational Site, Chongqing, China|202.848.86006 Boehringer Ingelheim Investigational Site, Guangzhou, China|202.848.86003 Boehringer Ingelheim Investigational Site, Hangzhou, China|202.848.86022 Boehringer Ingelheim Investigational Site, Huanggang, China|202.848.86001 Boehringer Ingelheim Investigational Site, Shanghai, China|202.848.86011 Boehringer Ingelheim Investigational Site, Shanghai, China|202.848.86015 Boehringer Ingelheim Investigational Site, Shenyang, China|202.848.86014 Boehringer Ingelheim Investigational Site, Shijiazhuang, China|202.848.86019 Boehringer Ingelheim Investigational Site, Wenzhou, China|202.848.86004 Boehringer Ingelheim Investigational Site, Wuhan, China|202.848.86005 Boehringer Ingelheim Investigational Site, Wuhan, China
- Other Id
- 202.848
- Start Date
- 2013-08
- Primary Completion Date
- 2015-02
- Completion Date
- 2015-02
- First Posted
- 2013-08-27
- Results First Posted
- 2016-03-08
- Last Update Posted
- 2016-03-08
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT01929044
- Title Cn
- Title En
- Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain
- Bilingual Status
- semi_complete